Urogen Pharma Ltd (URGN) Stock AnalysisURGNStock AnalysisUrogen Pharma Ltd

UroGen Pharma Ltd. Is an Israel-based biopharmaceutical company. The Company is engaged in building solutions for cancers and urologic diseases. UroGen has developed RTGelTM reverse-thermal hydrogel, a proprietary sustained release, hydrogel-based platform technology that has the potential to improve therapeutic profiles of existing drugs. Its lead product candidates include MitoGel and VesiGel are formulated using its proprietary reverse thermally triggered hydrogel, or RTGel, technology. MiroGel ( UGN-101) is a sustained release formulation of the chemotherapy agent Mitomycin C for the treatment of low-grade upper tract urothelial carcinoma, an urothelial cancer in the upper tract. VesiGel (UGN-102) is a sustained release formulation of a high dose Mitomycin C for the treatment of low grade non-muscle invasive bladder cancer (LG-NMIBC). It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Urogen Pharma Ltd is a good buy right now due to its significant revenue growth, with Q2 2026 revenue reported at $72.5 million, a 73% increase sequentially, and a narrowing net loss of $14.4 million. The stock is currently priced at $43.62, well below the average analyst target of $60, suggesting a potential upside of 37.5%. However, the current RSI of 25.308 indicates the stock is oversold, which may present a buying opportunity despite recent volatility.

4 analysts cover URGN: 3 rate it Buy, 1 Hold and 0 Sell. The average price target is 40.25.